About Progenity
Progenity is a company based in San Diego (United States) founded in 2011 by Harry Stylli. Progenity has raised $216.63 million across 9 funding rounds from investors including Athyrium Capital Management. The company has 125 employees. Progenity has completed 1 acquisition, including Carmenta Bio. Progenity offers products and services including BioJet and NaviCap. Progenity operates in a competitive market with competitors including Natera, BillionToOne, SYNLAB, Beikang Medical and Yourgene Health, among others.
- Headquarter San Diego, United States
- Employees 125
- Founders Harry Stylli
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website progenity.com
- Social LinkedIn X
- Legal Name Biora Therapeutics, Inc.
- Annual Revenue$1.25 M (USD)670as on Dec 31, 2021
- Total Equity Funding$216.63M (USD)
in 9 rounds
- Latest Funding Round$40M (USD), Post-IPO
May 2021
- Investors
- Employee Count125
- Investments & Acquisitions
Products & Services of Progenity
Progenity offers a comprehensive portfolio of products and services, including BioJet and NaviCap.
Provides needle-free oral delivery of large molecules for chronic diseases.
Enables targeted oral delivery of therapeutics in specific body areas.
Funding Insights of Progenity
Progenity has successfully raised a total of $216.63M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $40 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $216.63M
- Total Rounds 9
- Last Round Post-IPO — $40M
- First Round $13.5M
(Jun 2013)
- Investors Count 1
All 9 funding rounds of Progenity with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | $40M | Post-IPO | – | – | – |
| Feb 2021 | – | Post-IPO | – | – | – |
| Dec 2020 | $75M | Post-IPO | – | – | – |
| Apr 2020 | $10M | Series B | – | – | – |
| Nov 2019 | $31.12M | Series B | – | – | – |
| Sep 2019 | $25M | Series B | – | – | – |
| Nov 2017 | $125M | Series B | – | Athyrium Capital Management | – |
| Aug 2016 | $12M | Series B | – | – | – |
| Jun 2013 | $13.5M | Series B | – | Athyrium Capital Management | – |
1 investors in total: 1 institutional.
Investors in Progenity
Progenity has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Athyrium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed by the firm. | – | athyrium.com | New York, United States |
Investor details for Progenity
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Progenity
21 people are tracked at Progenity (6 in leadership, 14 in board & advisors, 1 in team); the tracked headcount is 125.
| Name | Role | Group |
|---|---|---|
Harry Stylli | Founder & CEO | Leadership |
Eric D’Esparbes | CFO | Leadership |
Robyn Hatton | VP, HR | Leadership |
Adi Mohanty | CEO | Leadership |
Chris Wahl | VP, Strategy & Business Development | Leadership |
Paul Shabram | Head of Technical Operations | Leadership |
Lynne Powell | Director | Board & advisors |
Brian Kotzin | Director | Board & advisors |
Bruce Sands | Clinical Advisor, Inflammatory Bowel Disease | Board & advisors |
William Sandborn | Chair, Clinical Advisory Board, Inflammatory Bowel Disease | Board & advisors |
William Chey | Clinical Advisor, SIBO & Functional Bowel Disorders | Board & advisors |
Satish Rao | Chair, Clinical Advisory Board, SIBO & Functional Bowel Disorders | Board & advisors |
Anthony Lembo | Clinical Advisor, SIBO & Functional Bowel Disorders | Board & advisors |
Geert D’Haens | Clinical Advisor, Inflammatory Bowel Disease | Board & advisors |
Mark Pimentel | Clinical Advisor, SIBO & Functional Bowel Disorders | Board & advisors |
Jill Howe | Director | Board & advisors |
Surbhi Sarna | Director | Board & advisors |
Séverine Vermeire | Clinical Advisor, Inflammatory Bowel Disease | Board & advisors |
Jeffrey Ferrell | Director | Board & advisors |
Jeffrey Alter | Chair, Board of Directors | Board & advisors |
1 more people are available in the full profile.
Complete people profiles for Progenity
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Progenity
Progenity has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Carmenta Bio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Diagnostics for women's health | carmentabio.com | Palo Alto, United States | 2012 | Apr 2015 | •••• |
Complete acquisition details for Progenity
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Progenity
5 dated milestones of Progenity across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Progenity is founded.
- Funding First funding round of $13.5M.
- Acquisition Acquires Carmenta Bio.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $40.0M.
Competitors of Progenity
Progenity operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, BillionToOne, SYNLAB, Beikang Medical and Yourgene Health, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| billiontoone.com | 2015 | San Francisco, United States | $388.62M | 47 | Provider of cell-free cancer liquid biopsy test | |
| synlab.com | 1998 | Munich, Germany | – | 28,693 | Provider of medical diagnosis and clinical laboratory analysis services | |
| basecare.cn | 2010 | Suzhou, China | $36.52M | – | NGS-based diagnostic solutions for neonatal screening are developed. | |
| yourgene-health.com | 2000 | Manchester, United Kingdom | – | 2 | Non-invasive prenatal genetic tests and genomic services are provided. | |
| sequenom.com | 1994 | San Diego, United States | – | 524 | Noninvasive prenatal testing using cell-free fetal nucleic acids is offered. | |
| pictordx.com | 2005 | Auckland, New Zealand | $11.1M | – | Immunodiagnostic products are developed via multiplexed assays. | |
| identifai-genetics.com | 2020 | Tel Aviv, Israel | $9.8M | – | Non-invasive prenatal screening for genetic syndromes is provided. | |
| berrygenomics.com | 2010 | Beijing, China | $16M | – | Next-generation sequencing solutions for genetic and oncology testing are developed. |
Detailed competitors of Progenity
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Progenity
Websites that share an audience with Progenity (progenity.com).
Websites whose visitors overlap most with Progenity. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
panoramatest.com | panoramatest.com | 100% | – | – | – |
forums.thebump.com | forums.thebump.com | 98% | – | – | – |
| cff.org | 59% | 211.4K | #262,012 | View details | |
medgadget.com | medgadget.com | 59% | – | – | – |
| news-medical.net | 40% | 680.7K | #40,879 | View details |
Latest news on Progenity
Complete news archive for Progenity
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Progenity
10 companies that operate in the same segment as Progenity (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Progenity
Progenity was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Progenity is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Harry Stylli is the current CEO of Progenity. They have also founded this company.
Progenity is a funded company, having raised a total of $216.63M across 9 funding rounds to date. The company's 1st funding round was a Series B of $13.5M, raised on Jun 2013.
Progenity has 125 employees.
Annual revenue of Progenity is $1.25M as on Dec 31, 2021.
Provider of non-invasive prenatal genomic testing. The companys diagnostic platform is based on genomics, epigenomics, proteomics, and metabolomics. The companys products include a Preparent carrier test for prenatal genetic disorders, an Innatal prenatal screen for chromosomal-related disorders, hereditary cancer risk prediction, and Resura prenatal test for detecting monogenic disorders. The company also developing precision medicine for prenatal, perinatal, oncology, and gastroenterology diseases.
Progenity's top competitors include Natera, BillionToOne and Pictor.
Progenity offers BioJet and NaviCap.
Progenity has made 1 acquisition, including Carmenta Bio.
Progenity has 1 investor. Key investors include Athyrium Capital Management.
Progenity operates through Biora Therapeutics, Inc..